Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 113

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 113
---
 permit the Selling Shareholder to offer the shares for resale from time to time. Except for the transactions contemplated by
the Purchase Agreement and the Registration Rights Agreement or as otherwise set forth in this prospectus, the Selling Shareholder has
not had any material relationship with us within the past three years.

The table below presents information regarding the Selling Shareholder
and the securities that it may offer from time to time under this prospectus. This table is prepared based on information supplied to
us by the Selling Shareholder, and reflects holdings as of April 1, 2025. The number of shares in the column “Maximum Number of
Ordinary Shares to be Offered Pursuant to this Prospectus” represents all of the Ordinary Shares (represented by Depositary Shares)
that the Selling Shareholder may offer under this prospectus. The Selling Shareholder may sell some, all or none of its shares in this
offering. We do not know how long the Selling Shareholder will hold the shares before selling them, and we currently have no agreements,
arrangements or understandings with the Selling Shareholder regarding the sale of any of the shares.

Beneficial ownership is determined in accordance with Rule 13d-3(d)
promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which the Selling Shareholder have
voting and investment power. The percentage of Ordinary Shares beneficially owned by the Selling Shareholder following the offering shown
in the table below is based on an aggregate of 25,617,408,922 Ordinary Shares outstanding as of April 1, 2025. Because the purchase price
of the Depositary Shares issuable under the Purchase Agreement is determined on each Fixed Purchase Date, with respect to a Fixed Purchase,
on the applicable VWAP Purchase Date, with respect to a VWAP Purchase, and on the applicable Additional VWAP Purchase Date, with respect
to an Additional VWAP Purchase, the number of shares that may actually be sold by us to the Selling Shareholder under the Purchase Agreement
may be fewer than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of the shares offered
by the Selling Shareholder pursuant to this prospectus.

We may amend or supplement
this prospectus from time to time in the future to update or change the Selling Shareholder list and the securities that may be resold.

Please see the section titled
“Plan of Distribution” for further information regarding the Selling Shareholder’s